As a member of the phenothiazine type of antipsychotics,<unk>  shares in general all allergic and toxic side-effects of chlorpromazine. A 2015 systematic review of the data on<unk>  conducted by the Cochrane Collaboration concluded that "there were no convincing differences between<unk>  and other antipsychotics" in the incidence of adverse effects.<unk>  causes early and late extrapyramidal side effects more often than placebo, and at a similar rate to other medium-potency antipsychotics and the atypical antipsychotic risperidone. When used for its strong antiemetic or antivertignosic effects in cases with associated brain injuries, it may obscure the clinical course and interferes with the diagnosis. High doses of<unk>  can cause temporary dyskinesia. As with other typical antipsychotics, permanent or lasting tardive dyskinesia is a risk. Discontinuation The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time. There is tentative evidence that discontinuation of antipsychotics can result in psychosis. It may also result in reoccurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped.
Perphenazine
Bolazine
Triazolam
Cyprazepam
Adatanserin
Atogepant
Primidone
Mebanazine